囊性纤维化成人骨密度纵向变化:系统综述与荟萃分析
合并分析显示腰椎骨密度年变化为-0.28%(95%CI:-0.56,-0.01),股骨颈为-0.90%(95%CI:-1.29,-0.52),股骨颈丢失率超过同龄预期。所有研究均早于CFTR调节剂广泛应用时代。
要点
- 成人囊性纤维化患者骨密度进行性下降,股骨颈年降幅-0.90%超过同龄预期。
- 腰椎年降幅较小,为-0.28%,股骨颈是骨丢失更显著部位。
- 纳入研究均早于CFTR调节剂普及,现代治疗时代的骨健康策略有待评估。
核心结论
- 成人囊性纤维化患者存在进行性骨密度丢失,股骨颈尤为显著,其速率超过同龄预期。
- 研究结果支持加强骨健康管理策略,并提示需在现代治疗时代评估CFTR调节剂对骨密度、骨折风险和监测策略的影响。
研究设计与样本
- 系统综述与荟萃分析(PROSPERO:CRD420251091118),检索MEDLINE、Embase、Cochrane和PubMed至2025年3月22日。
- 纳入报告至少2次间隔≥1年DXA扫描的观察性研究及随机试验对照臂,对象为未接受骨质疏松治疗的成人,排除肺移植后DXA。
主要发现
- 腰椎骨密度合并年变化为-0.28%/年(95%CI:-0.56,-0.01)。
- 股骨颈骨密度合并年变化为-0.90%/年(95%CI:-1.29,-0.52),丢失速率超过同龄预期。
- 异质性低至中等(腰椎I²=28.7%;股骨颈I²=44.5%),方法学质量总体较高,但混杂和不完整随访常见。
关键数值与推荐
- 主要结局为腰椎和股骨颈骨密度的年百分比变化,腰椎-0.28%/年、股骨颈-0.90%/年。
- 纳入标准要求至少2次DXA扫描间隔≥1年,且受试者未接受骨质疏松治疗、排除肺移植后DXA。
临床怎么用
- 提示应关注成人囊性纤维化患者的骨健康监测与干预,尤其是股骨颈骨密度。
- 所有纳入研究均早于CFTR调节剂广泛应用,现代治疗时代的骨密度变化和骨折风险需重新评估。
局限性
- 所有纳入研究均早于CFTR调节剂广泛应用,结果可能不反映现代治疗时代。
- 混杂和不完整随访在纳入研究中较常见。
- 仅10项研究进入荟萃分析,样本量有限(n=811)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improved survival in cystic fibrosis (CF) has increased the burden of cystic fibrosis-related bone disease (CFBD), yet the natural history of bone mineral density (BMD) decline remains poorly defined. We conducted a systematic review and meta-analysis (PROSPERO: CRD420251091118) to quantify longitudinal BMD changes in adults with CF. METHODS: MEDLINE, Embase, Cochrane, and PubMed were searched through March 22, 2025 for observational studies and control arms of randomized trials reporting ≥2 dual-energy X-ray absorptiometry (DXA) scans ≥1 year apart in adults not receiving osteoporosis therapy; post-lung transplant DXAs were excluded. The primary outcome was annual percent change in BMD at the lumbar spine (LS) and femoral neck (FN). Random-effects models were used; heterogeneity was assessed with I². RESULTS: Twelve studies (n = 811; mean age 21-31 years; mean follow-up 24 months) were included, with 10 contributing to meta-analysis. Pooled annual BMD change was -0.28%/year (95% CI: -0.56, -0.01) at the LS and -0.90%/year (95% CI: -1.29, -0.52) at the FN. Heterogeneity was low to moderate (I² = 28.7% LS; 44.5% FN). Methodological quality was generally high, though confounding and incomplete follow-up were common. All studies predated widespread CFTR modulator use. CONCLUSIONS: Adults with CF experience progressive BMD loss, particularly at the FN, where the observed rate exceeded that expected for age. These findings support enhanced bone health strategies and highlight the need to evaluate CFTR modulator effects, fracture risk, and optimal monitoring in the modern treatment era.
引用
- Selvarajah A, Dittrich A, Mohandas V, et al. Longitudinal changes in bone mineral density among adults with cystic fibrosis: a systematic review and meta-analysis. Osteoporos Int. 2026. PMID: 42909486. doi:10.1007/s00198-026-08243-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。